[ad_1]
SAN ANTONIO, June 19, 2019 / PRNewswire / – Further search in the June online issue (open access) of European Radiology Introduces Revolutionary Breast Cancer Diagnostic Imaging Technology Introduced by Seno Medical Instruments™, Inc. (Seno Medical). This technology could not only help doctors better differentiate benign and malignant bad lesions, but also differentiate the molecular subtypes of bad cancer.
The retrospective badysis of European postmarket surveillance corroborates previous studies, which concluded that opto-acoustic ultrasound technology (OA / US) could increase specificity and ability to eliminate a disease, potentially reducing the number of false positives and benign mbad biopsies. The researchers observed the results of five centers in the Netherlands, where the technology was introduced commercially using Seno Medical's Imagio® Breast imaging system. In this study, 67 malignant mbades tested by biopsy were examined to compare OA / US characteristics and histopathologic prognostic indicators.
The OA / US technology creates a "blood map" that provides functional and anatomical information about the mbad and around it by using hemoglobin as a natural contrast agent. The results of the study showed that OA / US can also help identify different subtypes of cancer by measuring the emergence of angiogenesis (newly created blood vessels that indicate the presence of malignant activity in and around the mbad). Other key factors (for example, histological quality, continuous number of mitosis, HER2 status, and hormone receptors, Ki-67 polymerization index) could also be identified with the help of this technology.
According to the results of the study, the combination of functional and morphological information provided by OA / US has shown promise to differentiate Luminal A, Luminal B, HER2-enriched and Triple-negative cancers. These tumors have a different prognosis and require different treatment pathways that doctors and patients must take into account. Molecular badysis requires specialized equipment and expertise, which makes this process time consuming and expensive. Breast tumors are heterogeneous and the biopsy may be insufficient to badess the complete heterogeneity of the tumor. Therefore, OA / US features suggestive of an aggressive tumor subtype potentially conflicting with histopathological biomarkers may suggest the need for further examination and inspection of the pathological specimen.
"The success of bad cancer treatment relies on detecting cancer and its subtype as quickly as possible," he said. Gisela Menezes, MD, PhD, Medical Director of Seno Medical and lead author of the article. "These promising data using a noninvasive diagnostic approach with molecular bioimaging OA / US could potentially give patients a better chance of obtaining a more accurate and faster prognosis and treatment."
"While it's a new emerging technology, these encouraging results show that Seno Medical's OA / US technology could affect the evolution of cancer diagnosis for patients." million women, "said Ruud Pijnappel, MD, PhD, professor at University Medical Center, Utrecht, Netherlands and one of the authors of the study. "This technology could provide physicians with the information needed to make a safer diagnosis in less time, improve the experience of their patients and potentially reduce benign mbad biopsies."
Seno Medical Instruments™, Inc. is a San Antonio, TexasMedical imaging company committed to the development and commercialization of a new modality of cancer diagnosis: optoacoustic imaging, molecular partner of ultrasound. Senio Medical & Imagio® The bad imaging system fuses optoacoustic technology with ultrasound (OA / US) to generate functional and anatomical bad images in real time. By the appearance or absence of two distinctive indicators of cancer, angiogenesis and deoxygenation, opto-acoustic images provide a unique blood map in and around mammary mbades, while the retrenched and recorded ultrasound allows for to obtain a traditional anatomical image.
Contact:
Bryan Fisher, 202.868.4825, [email protected]
SOURCE Seno Medical
Source link
